U.S., June 14 -- ClinicalTrials.gov registry received information related to the study (NCT07019181) titled 'Tislelizumab Combined With Chemotherapy for the Perioperative Treatment of Esophageal Squamous Carcinoma' on May 21.
Brief Summary: Evaluating the rate of pathologic complete remission in patients with squamous esophageal cancer treated perioperatively with tislelizumab in combination with chemotherapy
Study Start Date: July 30
Study Type: INTERVENTIONAL
Condition:
Esophagus Cancer
Intervention:
DRUG: Tislelizumab
Tislelizumab, 200mg, intravenously over 30 - 60 minutes, day 1 of every 3 weeks
DRUG: albumin-bound paclitaxel
albumin-bound paclitaxel 260mg/m2，day 1 of every 3 weeks
DRUG: Nedaplatin
Nedaplatin 80mg/m2&...